Allergan Sues Hi-Tech To Block Generic Lash Drug Latisse

Law360, New York (May 16, 2012, 7:17 PM EDT) -- Allergan Inc. filed its third patent infringement suit against Hi-Tech Pharmacal Co. Inc. in North Carolina federal court on Wednesday, its latest effort to block a generic version of the eyelash growth treatment Latisse.

Allergan claims Hi-Tech's abbreviated new drug application seeking permission to manufacture bimatoprost ophthalmic solution infringes its patent for the drug. The treatment is marketed as Latisse, which was released in December 2008 as a treatment for hypotrichosis of the eyelashes and has become popular with consumers who want longer or thicker lashes....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.